Tag:

Abilify

Latest Headlines

Latest Headlines

Otsuka spends $3.5B for Avanir--and patent-cliff protection

Otsuka's patent cliff is coming, with the expiration date on best-seller Abilify's IP shield just around the corner. But now, the Japanese pharma has signed a $3.5 billion agreement to pick up Avanir Pharmaceuticals that could help soften the blow.

Bristol-Myers, Otsuka ask judge to nix Abilify kickback suit

Did Bristol-Myers Squibb offer kickbacks and push Abilify for off-label uses? Some former sales reps-turned-whistleblowers claim it did. And given the fact that Bristol-Myers already paid $515 million to settle some off-label marketing claims related to Abilify, they say, the company violated its "we'll behave" promises to the feds.

Alkermes closer to launching once-monthly schizophrenia drug into a crowded market

Alkermes has taken another step toward the market with its long-acting version of the schizophrenia drug Abilify, filing for an approval with the FDA as it lays the foundation for a hoped-for launch in 2015.

UPDATED: Alkermes hits PhIII goal line with 'blockbuster' long-acting schizophrenia drug

Alkermes has crossed the finish line in a Phase III schizophrenia study of a long-acting version of Abilify, picking up the statistically significant results needed to back a new drug application later in the year.

The 10 best-selling drugs of 2013

It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.

Antipsychotics hike diabetes risk in kids, study finds

Watchdogs worried about antipsychotic use in children now have more ammo. A new study links the drugs with Type 2 diabetes. Published in the journal JAMA Psychiatry, the study found a threefold increase in diabetes risk for kids who take antipsychotic drugs compared with those taking other psychotropic drugs.

NICE nods for Eylea, Abilify; FDA panel backs new Cimzia use

The regulators have spoken on both sides of the Atlantic. And in both cases, we have winners--and we have losers.

Bristol-Myers' Abilify coupons prevail in health-plan lawsuit

A federal judge tossed out a lawsuit filed by health plans unhappy with Bristol-Myers Squibb's co-pay offers on Abilify. The insurers accused the drugmaker of racketeering and bribery for using coupons to combat generic versions of the antipsychotic drug.

Lundbeck, Otsuka's new Abilify Maintena to face entrenched rivals

Lundbeck has another chance to crow this week, now that its once-monthly version of Abilify has FDA approval. The agency nod comes fast on the heels of another, for the Danish drugmaker's alcohol addiction drug Selincro. This double victory opens the way for Lundbeck to transform turnaround promises into actual sales.

FDA pins approval on once-monthly version of blockbuster Abilify

U.S. regulators handed Otsuka Pharmaceutical and Lundbeck some good news today, stamping an approval on the two drugmakers' once-monthly version of the big-selling schizophrenia drug Abilify.